Discovery of 5-(or 6)-benzoxazoles and oxazolo[4,5-b]pyridines as novel candidate antitumor agents targeting hTopo IIα. 2021

Esin Karatas, and Egemen Foto, and Tugba Ertan-Bolelli, and Gozde Yalcin-Ozkat, and Serap Yilmaz, and Sanaz Ataei, and Fatma Zilifdar, and Ilkay Yildiz
Ankara University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Ankara, Turkey.

Discovery of novel anticancer drugs which have low toxicity and high activity is very significant area in anticancer drug research and development. One of the important targets for cancer treatment research is topoisomerase enzymes. In order to make a contribution to this field, we have designed and synthesized some 5(or 6)-nitro-2-(substitutedphenyl)benzoxazole (1a-1r) and 2-(substitutedphenyl)oxazolo[4,5-b]pyridine (2a-2i) derivatives as novel candidate antitumor agents targeting human DNA topoisomerase enzymes (hTopo I and hTopo IIα). Biological activity results were found very promising for the future due to two compounds, 5-nitro-2-(4-butylphenyl)benzoxazole (1i) and 2-(4-butylphenyl)oxazolo[4,5-b]pyridine (2i), that inhibited hTopo IIα with 2 µM IC50 value. These two compounds were also found to be more active than reference drug etoposide. However, 1i and 2i did not show any satisfactory cyctotoxic activity on the HeLa, WiDR, A549, and MCF7 cancer cell lines. Moreover, molecular docking and molecular dynamic simulations studies for the most active compounds were applied in order to understand the mechanism of inhibition activity of hTopo IIα. In addition, in silico ADME/Tox studies were performed to predict drug-likeness and pharmacokinetic properties of all the tested compounds.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D010080 Oxazoles Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions. Oxazole,1,3-Oxazolium-5-Oxides,Munchnones,1,3 Oxazolium 5 Oxides
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001583 Benzoxazoles Benzoxazole
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Esin Karatas, and Egemen Foto, and Tugba Ertan-Bolelli, and Gozde Yalcin-Ozkat, and Serap Yilmaz, and Sanaz Ataei, and Fatma Zilifdar, and Ilkay Yildiz
April 2009, Bioorganic & medicinal chemistry letters,
Esin Karatas, and Egemen Foto, and Tugba Ertan-Bolelli, and Gozde Yalcin-Ozkat, and Serap Yilmaz, and Sanaz Ataei, and Fatma Zilifdar, and Ilkay Yildiz
November 1978, Journal of medicinal chemistry,
Esin Karatas, and Egemen Foto, and Tugba Ertan-Bolelli, and Gozde Yalcin-Ozkat, and Serap Yilmaz, and Sanaz Ataei, and Fatma Zilifdar, and Ilkay Yildiz
October 1987, Journal of medicinal chemistry,
Esin Karatas, and Egemen Foto, and Tugba Ertan-Bolelli, and Gozde Yalcin-Ozkat, and Serap Yilmaz, and Sanaz Ataei, and Fatma Zilifdar, and Ilkay Yildiz
January 2022, Journal of agricultural and food chemistry,
Esin Karatas, and Egemen Foto, and Tugba Ertan-Bolelli, and Gozde Yalcin-Ozkat, and Serap Yilmaz, and Sanaz Ataei, and Fatma Zilifdar, and Ilkay Yildiz
June 2014, ACS medicinal chemistry letters,
Esin Karatas, and Egemen Foto, and Tugba Ertan-Bolelli, and Gozde Yalcin-Ozkat, and Serap Yilmaz, and Sanaz Ataei, and Fatma Zilifdar, and Ilkay Yildiz
September 2012, ACS medicinal chemistry letters,
Esin Karatas, and Egemen Foto, and Tugba Ertan-Bolelli, and Gozde Yalcin-Ozkat, and Serap Yilmaz, and Sanaz Ataei, and Fatma Zilifdar, and Ilkay Yildiz
April 2024, International journal of biological macromolecules,
Esin Karatas, and Egemen Foto, and Tugba Ertan-Bolelli, and Gozde Yalcin-Ozkat, and Serap Yilmaz, and Sanaz Ataei, and Fatma Zilifdar, and Ilkay Yildiz
January 2019, Pest management science,
Esin Karatas, and Egemen Foto, and Tugba Ertan-Bolelli, and Gozde Yalcin-Ozkat, and Serap Yilmaz, and Sanaz Ataei, and Fatma Zilifdar, and Ilkay Yildiz
November 1976, The Journal of organic chemistry,
Esin Karatas, and Egemen Foto, and Tugba Ertan-Bolelli, and Gozde Yalcin-Ozkat, and Serap Yilmaz, and Sanaz Ataei, and Fatma Zilifdar, and Ilkay Yildiz
May 2018, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!